MAGE genes: Prognostic indicators in AL amyloidosis patients

Liu, Yang; Wen, Lei; Ma, Ling; Kang, Ying; Liu, Kai‐Yan; Huang, Xiao‐Jun; Ruan, Guo‐Rui; Lu, Jin

doi:10.1111/jcmm.14475

Title: MAGE genes: Prognostic indicators in AL amyloidosis patients

Authors:

^[1]; Wen, Lei ^[1]; Ma, Ling ^[1]; Kang, Ying ^[1];

^[1];

^[2]; Ruan, Guo‐Rui ^[1]; Lu, Jin ^[3]

Peking University People's Hospital, Peking University Institute of Hematology Beijing China, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Beijing China, Collaborative Innovation Center of Hematology, Peking University Beijing China
Peking University People's Hospital, Peking University Institute of Hematology Beijing China, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Beijing China, Collaborative Innovation Center of Hematology, Peking University Beijing China, Peking‐Tsinghua Center for Life Sciences Academy for Advanced Interdisciplinary Studies, Peking University Beijing China, Collaborative Innovation Center of Hematology Soochow University Suzhou China
Peking University People's Hospital, Peking University Institute of Hematology Beijing China, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Beijing China, Collaborative Innovation Center of Hematology, Peking University Beijing China, Collaborative Innovation Center of Hematology Soochow University Suzhou China

Publication Date:: 2019-06-20

Sponsoring Org.:: USDOE

OSTI Identifier:: 1560211

Alternate Identifier(s):: OSTI ID: 1560212

Resource Type:: Published Article

Journal Name:: Journal of Cellular and Molecular Medicine

Additional Journal Information:: Journal Name: Journal of Cellular and Molecular Medicine Journal Volume: 23 Journal Issue: 8; Journal ID: ISSN 1582-1838

Publisher:: Wiley-Blackwell

Country of Publication:: Country unknown/Code not available

Language:: English

Citation Formats


                    Liu, Yang, Wen, Lei, Ma, Ling, Kang, Ying, Liu, Kai‐Yan, Huang, Xiao‐Jun, Ruan, Guo‐Rui, and Lu, Jin. MAGE genes: Prognostic indicators in AL amyloidosis patients.  Country unknown/Code not available: N. p., 2019. 
Web.  doi:10.1111/jcmm.14475.

Copy to clipboard


                    Liu, Yang, Wen, Lei, Ma, Ling, Kang, Ying, Liu, Kai‐Yan, Huang, Xiao‐Jun, Ruan, Guo‐Rui, & Lu, Jin. MAGE genes: Prognostic indicators in AL amyloidosis patients.  Country unknown/Code not available.  https://doi.org/10.1111/jcmm.14475

Copy to clipboard


                    Liu, Yang, Wen, Lei, Ma, Ling, Kang, Ying, Liu, Kai‐Yan, Huang, Xiao‐Jun, Ruan, Guo‐Rui, and Lu, Jin. Thu .  
"MAGE genes: Prognostic indicators in AL amyloidosis patients".  Country unknown/Code not available.  https://doi.org/10.1111/jcmm.14475.

Copy to clipboard


                    
@article{osti_1560211,

  title        = {MAGE genes: Prognostic indicators in AL amyloidosis patients},

  author       = {Liu, Yang and Wen, Lei and Ma, Ling and Kang, Ying and Liu, Kai‐Yan and Huang, Xiao‐Jun and Ruan, Guo‐Rui and Lu, Jin},

  abstractNote = {},

  doi          = {10.1111/jcmm.14475},

  journal      = {Journal of Cellular and Molecular Medicine},

  number       = 8,

  volume       = 23,

  place        = {Country unknown/Code not available},

  year         = {2019},

  month        = {6}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Publisher's Version of Record
https://doi.org/10.1111/jcmm.14475

Other availability

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Works referenced in this record:

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
journal, November 2012

Fernández de Larrea, C.; Kyle, R. A.; Durie, B. G. M.
Leukemia, Vol. 27, Issue 4
DOI: 10.1038/leu.2012.336

Immunotherapy for the treatment of multiple myeloma
journal, March 2017

Jung, Sung-Hoon; Lee, Hyun-Ju; Vo, Manh-Cuong
Critical Reviews in Oncology/Hematology, Vol. 111
DOI: 10.1016/j.critrevonc.2017.01.011

Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation
journal, September 1999

Comenzo, Raymond L.; Wally, Jeremy; Kica, Geraldina
British Journal of Haematology, Vol. 106, Issue 3
DOI: 10.1046/j.1365-2141.1999.01591.x

Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation
journal, July 2017

Muchtar, Eli; Dispenzieri, Angela; Lacy, Martha Q.
British Journal of Haematology, Vol. 178, Issue 6
DOI: 10.1111/bjh.14830

The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma
journal, January 2014

Zhang, Yao; Bao, Li; Lu, Jin
Molecular Cancer, Vol. 13, Issue 1
DOI: 10.1186/1476-4598-13-25

Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
journal, July 2017

Zhang, Chunlan; Huang, Xufei; Li, Jian
Blood Reviews, Vol. 31, Issue 4
DOI: 10.1016/j.blre.2017.03.002

Lactate dehydrogenase as a prognostic marker in AL amyloidosis: expected or unexpected?
journal, July 2017

Chim, Chor S.
British Journal of Haematology, Vol. 178, Issue 6
DOI: 10.1111/bjh.14835

The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burden
journal, August 2001

Comenzo, Raymond L.; Zhang, Yana; Martinez, Carmen
Blood, Vol. 98, Issue 3
DOI: 10.1182/blood.V98.3.714

Correlates of immune and clinical activity of novel cancer vaccines
journal, October 2018

van der Burg, Sjoerd H.
Seminars in Immunology, Vol. 39
DOI: 10.1016/j.smim.2018.04.001

The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients
journal, November 2014

Huang, X.; Wang, Q.; Jiang, S.
Clinical Kidney Journal, Vol. 8, Issue 1
DOI: 10.1093/ckj/sfu117

Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry
journal, January 2017

Kourelis, Taxiarchis V.; Dasari, Surendra; Theis, Jason D.
Blood, Vol. 129, Issue 3
DOI: 10.1182/blood-2016-10-743997

Targeting MAGE-C1/CT7 Expression Increases Cell Sensitivity to the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cell Lines
journal, November 2011

Carvalho, Fabricio de; Costa, Erico T.; Camargo, Anamaria A.
PLoS ONE, Vol. 6, Issue 11
DOI: 10.1371/journal.pone.0027707

Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain–associated amyloidosis (AL)
journal, May 2003

Abraham, Roshini S.; Geyer, Susan M.; Price-Troska, Tammy L.
Blood, Vol. 101, Issue 10
DOI: 10.1182/blood-2002-09-2707

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
journal, January 2005

Gertz, Morie A.; Comenzo, Ray; Falk, Rodney H.
American Journal of Hematology, Vol. 79, Issue 4
DOI: 10.1002/ajh.20381

Treatment of Immunoglobulin Light Chain Amyloidosis
journal, August 2015

Dispenzieri, Angela; Buadi, Francis; Kumar, Shaji K.
Mayo Clinic Proceedings, Vol. 90, Issue 8
DOI: 10.1016/j.mayocp.2015.06.009

Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma
journal, February 2009

Atanackovic, D.; Luetkens, T.; Hildebrandt, Y.
Clinical Cancer Research, Vol. 15, Issue 4
DOI: 10.1158/1078-0432.CCR-08-0989

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
journal, December 2012

Palladini, Giovanni; Dispenzieri, Angela; Gertz, Morie A.
Journal of Clinical Oncology, Vol. 30, Issue 36
DOI: 10.1200/JCO.2011.37.7614

MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer
journal, July 2011

von Boehmer, Lotta; Keller, Lukas; Mortezavi, Ashkan
PLoS ONE, Vol. 6, Issue 7
DOI: 10.1371/journal.pone.0021366

Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma
journal, October 2010

Pabst, Caroline; Zustin, Jozef; Jacobsen, Frank
Experimental and Molecular Pathology, Vol. 89, Issue 2
DOI: 10.1016/j.yexmp.2010.06.011

Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival
journal, May 2016

Muchtar, E.; Dispenzieri, A.; Kumar, S. K.
Leukemia, Vol. 31, Issue 1
DOI: 10.1038/leu.2016.140

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains
journal, September 2017

Sidana, S.; Tandon, N.; Dispenzieri, A.
Leukemia, Vol. 32, Issue 3
DOI: 10.1038/leu.2017.286

Cancer-testis antigen expression and immunogenicity in AL amyloidosis
journal, September 2012

Rosenzweig, M. A.; Landau, H.; Seldin, D.
Blood Cancer Journal, Vol. 2, Issue 9
DOI: 10.1038/bcj.2012.32

Is immunotherapy here to stay in multiple myeloma?
journal, January 2017

Rodríguez-Otero, Paula; Paiva, Bruno; Engelhardt, Monika
Haematologica, Vol. 102, Issue 3
DOI: 10.3324/haematol.2016.152504

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
journal, April 2010

Kyle, R. A.; Durie, B. G. M.; Rajkumar, S. V.
Leukemia, Vol. 24, Issue 6
DOI: 10.1038/leu.2010.60

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
journal, April 2012

Comenzo, R. L.; Reece, D.; Palladini, G.
Leukemia, Vol. 26, Issue 11
DOI: 10.1038/leu.2012.100

Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category
journal, December 2016

Muchtar, E.; Dispenzieri, A.; Kumar, S. K.
Leukemia, Vol. 31, Issue 7
DOI: 10.1038/leu.2016.369

Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients
journal, August 2016

Shires, Karen; Wienand, Kirsty
Journal of Cancer Research and Clinical Oncology, Vol. 142, Issue 11
DOI: 10.1007/s00432-016-2231-3

Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells
journal, December 2009

Atanackovic, D.; Hildebrandt, Y.; Jadczak, A.
Haematologica, Vol. 95, Issue 5
DOI: 10.3324/haematol.2009.014464

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
journal, November 2014

Rajkumar, S. Vincent; Dimopoulos, Meletios A.; Palumbo, Antonio
The Lancet Oncology, Vol. 15, Issue 12
DOI: 10.1016/S1470-2045(14)70442-5

Genome-wide analysis of cancer/testis gene expression
journal, December 2008

Hofmann, O.; Caballero, O. L.; Stevenson, B. J.
Proceedings of the National Academy of Sciences, Vol. 105, Issue 51
DOI: 10.1073/pnas.0810777105

T cell-based targeted immunotherapies for patients with multiple myeloma: Immunotargets in MM patients
journal, September 2014

Wang, Lei; Jin, Nan; Schmitt, Anita
International Journal of Cancer, Vol. 136, Issue 8
DOI: 10.1002/ijc.29190

MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy
journal, November 2012

de Carvalho, Fabricio; Alves, Veruska L. F.; Braga, Walter M. T.
Cancer Immunology, Immunotherapy, Vol. 62, Issue 1
DOI: 10.1007/s00262-012-1376-4

Similar Records in DOE PAGES and OSTI.GOV collections:

A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960 Patients in the RTOG Database

Journal Article Sperduto, Paul W. ; Berkey, Brian M.S. ; Gaspar, Laurie E ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: The purpose of this study is to introduce a new prognostic index for patients with brain metastases and compare it with three published indices. Treatment for brain metastases varies widely. A sound prognostic index is thus important to guide both clinical decision making and outcomes research. Methods and Materials: A new index was developed because of limitations in the three existing indices and new data (Radiation Therapy Oncology Group 9508) are available since the others were developed. All four indices were compared using the Radiation Therapy Oncology Group database of 1,960 patients with brain metastases from five randomized trials.more »« less
https://doi.org/10.1016/j.ijrobp.2007.06.074
The time frame of Epstein-Barr virus latent membrane protein-1 gene to disappear in nasopharyngeal swabs after initiation of primary radiotherapy is an independently significant prognostic factor predicting local control for patients with nasopharyngeal carcinoma

Journal Article Lin, S -Y ; Chang, K -P ; Graduate Institute of Clinical Medical Sciences, Chang Gung University, Linkou, Taiwan ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: The presence of Epstein-Barr virus latent membrane protein-1 (LMP-1) gene in nasopharyngeal swabs indicates the presence of nasopharyngeal carcinoma (NPC) mucosal tumor cells. This study was undertaken to investigate whether the time taken for LMP-1 to disappear after initiation of primary radiotherapy (RT) was inversely associated with NPC local control. Methods and Materials: During July 1999 and October 2002, there were 127 nondisseminated NPC patients receiving serial examinations of nasopharyngeal swabbing with detection of LMP-1 during the RT course. The time for LMP-1 regression was defined as the number of days after initiation of RT for LMP-1 results tomore »« less
https://doi.org/10.1016/J.IJROBP.2005.0
A robust gene expression-based prognostic risk score predicts overall survival of lung adenocarcinoma patients

Journal Article Chen, En-Guo ; Wang, Pin ; Lou, Haizhou ; ... - Oncotarget

Identification of reliable predictive biomarkers and new therapeutic targets is a critical step for significant improvement in patient outcomes. Here, we developed a multi-step bioinformatics analytic strategy to mine large omics and clinical data to build a prognostic scoring system for predicting the overall survival (OS) of lung adenocarcinoma (LuADC) patients. In latter we first identified 1327 significantly and robustly deregulated genes, 600 of which were significantly associated with the OS of LuADC patients. Gene co-expression network analysis revealed the biological functions of these 600 genes in normal lung and LuADCs, which were found to be enriched for cell cycle-relatedmore »« less
https://doi.org/10.18632/oncotarget.23490

Full Text Available
Structure, chromosomal localization, and expression of 12 genes of the MAGE family

Journal Article De Plaen, E ; Szikora, J P ; De Smet, C ; ... - Immunogenetics

The authors reported previously that human gene MAGE-1 directs the expression of a tumor antigen recognized on a melanoma by autologous cytolytic T lymphocytes. Probing cosmid libraries with a MAGE-1 sequence, they identified 11 closely related genes. The analysis of hamster-human somatic cell hybrids indicated that the 12 MAGE genes are located in the q terminal region of chromosome X. Like MAGE-1, the 11 additional MAGE genes have their entire coding sequence located in the last exon, which shows 64%-85% identity with that of MAGE-1. The coding sequences of the MAGE genes predict the same main structural features for allmore »« less
https://doi.org/10.1007/BF01246677
The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28

Journal Article Rogner, U C ; Wilke, K ; Steck, E ; ... - Genomics

The melanoma antigen gene (MAGE) family comprises 12 known genes, of which 6 are expressed in tumors. In the course of a systematic analysis of transcripts in Xq28, we have identified cDNAs related to different MAGE genes. Analysis of cell hybrids, ordered YACs, and cosmids showed that all MAGE genes are located in Xq28 and are clustered in three main intervals within 3.5 Mb. The six genes expressed in tumors are contained in the two intervals closest to the telomere and are highly homologous to each other. Analysis of different species suggests that human MAGE sequences are conserved in primates,more »« less
https://doi.org/10.1006/geno.1995.9945

Similar Records

Title: MAGE genes: Prognostic indicators in AL amyloidosis patients

Citation Formats

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group journal, November 2012

Immunotherapy for the treatment of multiple myeloma journal, March 2017

Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation journal, September 1999

Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation journal, July 2017

The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma journal, January 2014

Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role? journal, July 2017

Lactate dehydrogenase as a prognostic marker in AL amyloidosis: expected or unexpected? journal, July 2017

The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burden journal, August 2001

Correlates of immune and clinical activity of novel cancer vaccines journal, October 2018

The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients journal, November 2014

Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry journal, January 2017

Targeting MAGE-C1/CT7 Expression Increases Cell Sensitivity to the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cell Lines journal, November 2011

Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain–associated amyloidosis (AL) journal, May 2003

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis journal, January 2005

Treatment of Immunoglobulin Light Chain Amyloidosis journal, August 2015

Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma journal, February 2009

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes journal, December 2012

MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer journal, July 2011

Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma journal, October 2010

Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival journal, May 2016

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains journal, September 2017

Cancer-testis antigen expression and immunogenicity in AL amyloidosis journal, September 2012

Is immunotherapy here to stay in multiple myeloma? journal, January 2017

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management journal, April 2010

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis journal, April 2012

Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category journal, December 2016

Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients journal, August 2016

Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells journal, December 2009

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma journal, November 2014

Genome-wide analysis of cancer/testis gene expression journal, December 2008

T cell-based targeted immunotherapies for patients with multiple myeloma: Immunotargets in MM patients journal, September 2014

MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy journal, November 2012

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
journal, November 2012

Immunotherapy for the treatment of multiple myeloma
journal, March 2017

Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation
journal, September 1999

Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation
journal, July 2017

The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma
journal, January 2014

Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
journal, July 2017

Lactate dehydrogenase as a prognostic marker in AL amyloidosis: expected or unexpected?
journal, July 2017

The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burden
journal, August 2001

Correlates of immune and clinical activity of novel cancer vaccines
journal, October 2018

The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients
journal, November 2014

Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry
journal, January 2017

Targeting MAGE-C1/CT7 Expression Increases Cell Sensitivity to the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cell Lines
journal, November 2011

Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain–associated amyloidosis (AL)
journal, May 2003

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
journal, January 2005

Treatment of Immunoglobulin Light Chain Amyloidosis
journal, August 2015

Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma
journal, February 2009

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
journal, December 2012

MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer
journal, July 2011

Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma
journal, October 2010

Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival
journal, May 2016

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains
journal, September 2017

Cancer-testis antigen expression and immunogenicity in AL amyloidosis
journal, September 2012

Is immunotherapy here to stay in multiple myeloma?
journal, January 2017

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
journal, April 2010

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
journal, April 2012

Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category
journal, December 2016

Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients
journal, August 2016

Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells
journal, December 2009

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
journal, November 2014

Genome-wide analysis of cancer/testis gene expression
journal, December 2008

T cell-based targeted immunotherapies for patients with multiple myeloma: Immunotargets in MM patients
journal, September 2014

MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy
journal, November 2012